Mural Oncology plc (MURA) Stock
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
About Mural Oncology plc
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Mural Oncology plc is headquartered in IE.
Mural Oncology plc (MURA) stock trades at $2.04 with a market capitalization of $35.38M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.41, reflecting a net loss over the last twelve months, price-to-book of 0.64, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.95 and $4.74, and currently trades 57.0% below its 52-week high.
On profitability, Mural Oncology plc generates a return on equity (ROE) of -114.70% (negative, reflecting a net loss), return on capital employed of -126.21%.
Official website: www.muraloncology.com
Mural Oncology plc by the numbers, 2021–2024
Between 2021 and 2024 Mural Oncology plc reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit rose to $-129.0M.
On a trailing twelve-month basis to Sep '25, revenue is $0 and net profit $-119.0M.
Borrowings fell from $25.0M to $8.0M, cash on hand is $58.9M, cash from operations was $-129.0M in the latest year, positive in 0 of the last 4.
Return on equity has averaged 416.5% over five years, and was -91.5% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Mural Oncology plc (MURA) — frequently asked questions
What is Mural Oncology plc (MURA) stock price today?
Mural Oncology plc (MURA) is currently trading at $2.04, up 0% today.
What is MURA P/E ratio?
Mural Oncology plc's P/E ratio is -0.41. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is MURA return on equity (ROE)?
Mural Oncology plc's return on equity (ROE) is -114.70%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Mural Oncology plc's market cap?
Mural Oncology plc has a market capitalization of $35.38M.
Does MURA pay a dividend?
Mural Oncology plc is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does MURA carry?
Mural Oncology plc has a debt-to-equity ratio of 0.06. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is MURA's profit margin?
Mural Oncology plc reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is MURA in?
Mural Oncology plc is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is MURA listed on?
Mural Oncology plc trades on NASDAQ under the ticker MURA.
What is MURA's 52-week range?
Over the last year Mural Oncology plc has traded between $0.95 and $4.74.
Related Healthcare Stocks
Popular Stocks
Screens MURA currently matches
On the figures above, Mural Oncology plc passes the filters for 2 of our ready-made screens, among them Penny Stocks, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.